JP Morgan Chase
AMED

JP Morgan Chase’s Amedisys AMED Stock Holding History

JP Morgan Chase’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-192,900
Closed -$19M – 7372
2025
Q2 		$19M Hold
192,900
– – ﹤0.01% 1994
2025
Q1 		$17.9M Buy
192,900
+64,900
+51% +$5.98M ﹤0.01% 2015
2024
Q4 		$11.6M Buy
+128,000
New +$11.8M ﹤0.01% 2555

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's AMED Position: Q3 2025 in Review

JP Morgan Chase sold out of Amedisys (AMED) in Q3 2025, closing a stake of 126,588 shares — an estimated $12.5M sold.

JP Morgan Chase first reported a position in AMED in Q2 2013 and held it in 47 quarters. The position peaked at $334M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • JP Morgan Chase reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 126,588 Amedisys shares in Q3 2025, an estimated $12.5M.
  • JP Morgan Chase first reported a position in Amedisys in Q2 2013 and held it in 47 quarters.
  • JP Morgan Chase's Amedisys position peaked at $334M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.